# A Study to Evaluate the Efficacy and Safety of AD-223

> **NCT06052748** · PHASE3 · COMPLETED · sponsor: **Addpharma Inc.** · enrollment: 502 (actual)

## Conditions studied

- Hypertension,Essential

## Interventions

- **DRUG:** AD-223A
- **DRUG:** AD-223B
- **DRUG:** AD-223C
- **DRUG:** AD-223A Placebo
- **DRUG:** AD-223B Placebo
- **DRUG:** AD-223C Placebo

## Key facts

- **NCT ID:** NCT06052748
- **Lead sponsor:** Addpharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-15
- **Primary completion:** 2025-03-27
- **Final completion:** 2025-04-02
- **Target enrollment:** 502 (ACTUAL)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06052748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06052748, "A Study to Evaluate the Efficacy and Safety of AD-223". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06052748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*